Genomate Health

04/23/2026

Testicular cancer is one of the few cancers where early detection can dramatically change outcomes.

Yet too often, diagnosis still happens later than it should.

Awareness is not just about knowing the risk. It’s about understanding the disease early enough to act with clarity and confidence. At Genomate Health, we believe better cancer care starts with a deeper understanding of each patient’s disease, not as isolated signals, but as a complete biological system.

This month is a reminder that early detection matters.
But so does getting the full picture: https://shorturl.at/rymc2

04/22/2026

Behind every abstract is a simple goal: helping patients receive better, more informed treatment.

At , we’re proud to contribute with: 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐮𝐭𝐢𝐥𝐢𝐭𝐲 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐨𝐟 𝐚 𝐜𝐨𝐦𝐩𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐫𝐞𝐚𝐬𝐨𝐧𝐢𝐧𝐠 𝐬𝐲𝐬𝐭𝐞𝐦 𝐨𝐧 𝐥𝐚𝐫𝐠𝐞-𝐬𝐜𝐚𝐥𝐞 𝐭𝐮𝐦𝐨𝐫 𝐠𝐞𝐧𝐨𝐦𝐢𝐜 𝐝𝐚𝐭𝐚 https://www.asco.org/abstracts-presentations/263141

This work focuses on a critical question: how can we better understand each patient’s cancer (in its full complexity) to support more confident treatment decisions?

Because for us, it’s not about data. It’s about clarity, options, and time for what matters.

Full abstracts will be released on May 21. We look forward to sharing more.

04/21/2026

This is a big one for us.

Out of 135+ startups from around the world, Genomate Health has been selected as one of just 7 finalists to pitch at the C3 International x King Faisal Specialist Hospital and Research Center Innovation Challenge. To be in this room, with this level of clinical partner, and this level of competition, says a lot about where we are.

And the timing makes it even more meaningful.

This week, we’re at , presenting our latest findings.
Next week, we’re taking the stage at Plug and Play Tech Center.
From research to real-world application, back to back.

This is how we’ve always believed cancer care progress should happen: not in isolation, but as a continuous line from discovery to impact. It’s a strong signal that what we’re building is resonating where it matters most: advancing how cancer is understood, and how decisions get made.

Next week, in Silicon Valley, our founder, Istvan Petak MD, PhD, is going to show why a complete, system-level understanding of cancer isn’t optional anymore, and what becomes possible when you finally have it in clinical practice.

If you’re around, come see it live on April 27:https://lnkd.in/d-fAKyp8 (Code: C3PLUGANDPLAY)

04/15/2026

On our way to !

At AACR this year, we’re bringing computational reasoning into the spotlight, with new data spanning cell lines, real-world cohorts, and multidisciplinary clinical practice.

Here’s what we’re presenting:

🔬 From data to decision (GDSC): Molecularly informed prediction of treatment efficacy https://www.genomate.health/publication/genomate-treatment-efficacy-predictivity-in-gdsc-cell-line-data

🔬 From cohorts to clinic (GENIE NSCLC): Predicting treatment response in real-world patients https://www.genomate.health/publication/genomate-treatment-efficacy-predictivity-in-genie-bpc-nsclc-cohort

🔬 Late-breaking | Real-world impact: How computational reasoning supports tumour board decisions across cancershttps://www.abstractsonline.com/pp8/ #!/21436/presentation/11352

If you're at AACR and want to talk about making sense of cancer complexity (for real), meet our founder & CSO, Dr. Istvan Petak: https://nltxg.share.hsforms.com/2cQtUiHEWQHWldh4IAS_pFw

Let’s move beyond data, towards decisions, by connecting molecular insights, real-world evidence, and clinical reasoning into actionable treatment strategies.

04/13/2026

April marks Head and Neck Cancer Awareness Month, a reminder of how complex and often overlooked these cancers are. Head and neck cancers are not a single disease, but a group of biologically diverse cancers affecting areas like the oral cavity, throat, and larynx. Their complexity is one of the reasons they remain difficult to diagnose and treat.

Incidence continues to rise globally, with rates increasing significantly over the past decades. But the real challenge goes deeper. Each patient’s disease can look similar clinically, yet behave very differently at the molecular level. That’s why moving beyond surface-level diagnosis matters.

At Genomate Health, we focus on understanding cancer as a system, bringing together the full molecular picture to support more informed, personalized treatment decisions. If you or a loved one is facing a diagnosis, getting a deeper, more complete perspective can make a difference.

Learn more about our Second Opinion Service and how it can help guide your next step: https://www.genomate.health/services/second-opinion

04/10/2026

Can we systematically rank cancer therapies based on tumor biology?

At , we’re presenting evidence that this is possible.
Using computational reasoning on large-scale GDSC cell line data, we evaluated how combinations of molecular alterations relate to drug response, and translated that into therapy rankings.

What matters is not just identifying mutations, but understanding how they interact to shape treatment efficacy. The result: a consistent link between Genomate scores and experimental sensitivity, showing that therapies can be stratified by their likelihood of working.

Dive into the data before we meet: https://genomate.health/publication/genomate-treatment-efficacy-predictivity-in-gdsc-cell-line-data
📍 Poster 2719
🗓 April 20, 2026
⏰ 2:00–5:00 PM

Robert Doczi, PhD, Akos Takacs, Anna Dirner, Dóra Lakatos PhD, Barbara Vodicska, PhD, Dóra Tihanyi, Réka Szalkai-Dénes, Enikő Kispéter, Makkos András, Aniko Gorbe, Prof. Péter Ferdinandy, MD, PhD, MBA, William T Beck, Christophe Le Tourneau, Istvan Petak MD, PhD

04/09/2026

Can we predict which cancer treatments will actually work in real patients?

That’s the question behind our latest research, presented at .

We applied Genomate’s computational reasoning approach to NSCLC data from the AACR Project GENIE Biopharma Collaborative to test whether treatment efficacy can be anticipated from complex molecular profiles, and validated it against real-world clinical outcomes.

The takeaway? We can systematically distinguish between therapies that are more likely to benefit patients and those that are not. If you’re interested in what this means in practice, the key findings are in the carousel below.

Dive into the data before we meet: https://genomate.health/publication/genomate-treatment-efficacy-predictivity-in-genie-bpc-nsclc-cohort
Section: AACR Project GENIE: Predictive Models and AI
📍 Poster 7
🗓 April 19, 2026
⏰ 2:00 - 5:00 PM

Barbara Vodicska, PhD, Enikő Kispéter, Dóra Lakatos PhD, Gabor Gyorgy Kalmar, Robert Doczi, PhD, Dóra Tihanyi, Anna Dirner, Réka Szalkai-Dénes, William T Beck, Arkadiusz Z. Dudek, Christophe Le Tourneau, Istvan Petak MD, PhD

04/07/2026

This World Health Day, we’re standing with science 💚

Better outcomes start with better understanding, and every patient deserves care shaped by evidence, collaboration, and progress.

World Health Organization (WHO)

04/03/2026

Precision oncology holds enormous promise, but for many patients, the reality is still fragmented, complex, and difficult to navigate. Too often, treatment decisions are based on partial insights, leaving both patients and clinicians without the full picture of the disease.

This La Presse article touches on a critical shift: moving beyond isolated mutations toward a more complete, integrated understanding of cancer. At Genomate Health, we focus on exactly this challenge: helping make sense of the full molecular complexity of each patient’s cancer so that decisions are clearer, more confident, and truly personalized.

Merci de nous avoir cités et d'avoir mis en lumière ces enjeux cruciaux pour les patients, Mathieu Perreault !

Read the full article here:

Parmi les dizaines de milliers de médicaments dont le brevet est expiré, certains ont des effets anticancer. Ils sont toutefois souvent ignorés dans les plans de traitement, faute d’être assez rentables. Une biologiste américaine veut changer la donne grâce à l’IA et faire en sorte que sa...

03/31/2026

We’re proud to contribute to , an Innovative Health Initiative (IHI) project bringing together more than 60 partners across Europe and beyond.

Over the next five years, COMPASS will work to improve outcomes for cancer patients by enabling earlier risk prediction, more coordinated care, and truly personalized treatment pathways.

At Genomate Health, we’re contributing our computational reasoning approach to help translate complex molecular data into clinically actionable insights, supporting better decisions across the patient journey.

Together, we’re helping bridge oncology and cardiovascular care to improve both cancer outcomes and long-term health. Learn more: https://www.genomate.health/news-article/genomate-health-contributes-to-eu-funded-compass-project

03/30/2026

Colorectal cancer is changing, and we need to pay attention.

Once considered a disease of older adults, it is now rising in younger populations, increasing by ~3% each year in people under 50. Today, nearly 1 in 5 cases is diagnosed before age 55.

The bigger problem? Many younger patients are diagnosed too late, because they don’t expect cancer, and neither does the system.

What to watch for:
• Persistent changes in bowel habits
• Blood in stool
• Unexplained weight loss or fatigue
• Ongoing abdominal discomfort
If something feels off, don’t ignore it. Push for answers.

At Genomate Health, we help patients and doctors get clearer answers about what’s driving each cancer, so they can make the right decisions, faster. Because when diagnosis comes late, every decision matters.

It’s time our understanding and our actions catch up with the reality of this disease.

03/24/2026

You don’t just want more information.
You want to feel sure.

After a cancer diagnosis, it’s normal to question everything: Is this the right treatment? Is there something we’re missing?

At Genomate Health, we’re here to help you find clarity.
Our Second Opinion Service looks at your cancer in its full complexity, combining advanced computational reasoning with expert clinical insight, so you can better understand your options and move forward with confidence.

Not just more data. A complete picture.
Because better insight leads to better decisions.

Learn more: https://www.genomate.health/services/second-opinion